Company Information

  

Address: 111 WEST LEMON AVE  
City: MONROVIA 
State: CA 
Zip Code: 91016 
Telephone: 626-305-5900 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical­stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody therapeutics to treat severe and life­threatening diseases with unmet medical needs. We have developed a proprietary XmAb® technology platform that we use to create next­generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. In contrast to conventional approaches to antibody design, which focus on the portion of antibodies that interact with target antigens, we focus on the portion of the antibody that interacts with multiple segments of the immune system and controls antibody structure. This portion, referred to as the Fc domain, is constant and interchangeable among antibodies. Our engineered Fc domains, the XmAb technology, can be readily substituted for natural Fc domains.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-1.34NAN/E
12/2017-1.05NAN/E
09/2017-1.01NAN/E
06/2017-0.88NAN/E
03/20170.42NA56.95
12/20160.56NA47.00
09/20160.99NA24.74
06/20160.94NA20.20

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.09Total Liab/Total Assets0.28
Net Inc/Total Assets-0.13Total Liab/Inv Cap0.37
Net Inc/Inv Cap-0.17Total Liab/Comm Equity0.19
Pretax Inc/Net Sales-1.38Interest Coverage Ratio-3798.08
Net Inc/Net Sales-1.37Curr Debt/EquityNA
Cash Flow/Net Sales-0.94LTD/EquityNA
SG&A/NetSales0.49Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover7.32Quick Ratio2.28
Inventory TurnoverNACurrent Ratio2.28
Inventory Day SalesNANet Rec/Curr Assets0.00
Net Sales/Work Cap0.28Inv/Curr AssetsNA
Net Sales/PP&E5.04  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 0.00 10.94 7.09 14.18
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 4.56 4.43 4.17 4.09
Operating Income -30.65 -13.88 -16.49 -6.83
Interest Exp 0.00 0.01 0.00 0.00
Pretax Income -29.49 -12.93 -15.39 -5.76
Other Income 1.16 0.96 1.10 1.07
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -29.49 -11.84 -15.56 -6.04

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 462.41 224.13 209.95 188.49
Receivables - Total 1.86 1.14 0.83 14.88
Inventories - Total NA NA NA NA
Total Current Assets 470.92 230.88 217.81 210.98
Net Property, Plant & Equipment 8.92 7.09 6.09 3.86
Total Assets 612.27 390.10 398.26 416.16
Liabilities        
Accounts Payable 13.13 12.51 11.24 11.82
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 73.43 101.35 100.33 107.43
Long-Term Debt NA NA NA NA
Total Liabilities 74.61 108.06 107.72 114.80
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.56 0.47 0.47 0.47
Retained Earnings -282.36 -287.29 -275.44 -259.88
Treasury Stock NA NA NA NA
Total Stockholders' Equity 537.66 282.05 290.54 301.37
Total Liabilities and Stockholders' Equity 612.27 390.10 398.26 416.16

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -24.25 -6.67 -3.51 -12.96
Net Cash Provided by Investing Activities 12.67 8.94 4.93 9.53
Net Cash Provided by Financing Activities 246.62 0.62 0.99 1.10

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201310.17-60.26--
12/20149.52-16.42-0.52
12/201527.76-17.59-0.45
12/201687.5223.620.56
12/201735.71-48.92-1.05
Growth Rates36.88----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1813744,98480.87




Report Date : 7/10/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.